Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Department of Neurology, Xinxiang Medical University, Xinxiang, 453100, China.
Mol Psychiatry. 2023 Nov;28(11):4877-4888. doi: 10.1038/s41380-023-02145-5.
We previously reported that prolonged exposure to an enriched environment (EE) enhances hippocampal synaptic plasticity, with one of the significant mechanistic pathways being activation of β-adrenergic receptor (β-AR) signaling, thereby mitigating the synaptotoxic effects of soluble oligomers of amyloid β-protein (oAβ). However, the detailed mechanism remained elusive. In this work, we recorded field excitatory postsynaptic potentials (fEPSP) in the CA1 region of mouse hippocampal slices treated with or without toxic Aβ-species. We found that pharmacological activation of β-AR, but not β-AR, selectively mimicked the effects of EE in enhancing LTP and preventing oAβ-induced synaptic dysfunction. Mechanistic analyses showed that certain histone deacetylase (HDAC) inhibitors mimicked the benefits of EE, but this was not seen in β-AR knockout mice, suggesting that activating β-AR prevents oAβ-mediated synaptic dysfunction via changes in histone acetylation. EE or activation of β-ARs each decreased HDAC2, whereas Aβ oligomers increased HDAC2 levels in the hippocampus. Further, oAβ-induced inflammatory effects and neurite degeneration were prevented by either β-AR agonists or certain specific HDAC inhibitors. These preclinical results suggest that activation of β-AR is a novel potential therapeutic strategy to mitigate oAβ-mediated features of AD.
我们之前曾报道过,长时间暴露于丰富环境(EE)会增强海马突触可塑性,其中一个重要的机制途径是激活β-肾上腺素能受体(β-AR)信号,从而减轻淀粉样β蛋白(Aβ)可溶性寡聚物的突触毒性作用。然而,其详细机制仍不清楚。在这项工作中,我们记录了经或未经有毒 Aβ 物质处理的小鼠海马切片 CA1 区的场兴奋性突触后电位(fEPSP)。我们发现,β-AR 的药理学激活,而不是β-AR,选择性地模拟了 EE 增强 LTP 和防止 oAβ 诱导的突触功能障碍的作用。机制分析表明,某些组蛋白去乙酰化酶(HDAC)抑制剂模拟了 EE 的益处,但在β-AR 敲除小鼠中并未见到,这表明激活β-AR 通过组蛋白乙酰化的变化来防止 oAβ 介导的突触功能障碍。EE 或β-AR 的激活均降低了 HDAC2,而 Aβ 寡聚物增加了海马中的 HDAC2 水平。此外,β-AR 激动剂或某些特定的 HDAC 抑制剂均可预防 oAβ 诱导的炎症作用和神经突退化。这些临床前结果表明,激活β-AR 是一种减轻 oAβ 介导的 AD 特征的新型潜在治疗策略。